Pharmacoepidemiology and Drug Safety in 2026

Pharmacoepidemiology and Drug Safety in 2026

Updated 15 July 2026. Pharmacoepidemiology studies the use, effectiveness and safety of medicines in real-world clinical practice. It complements spontaneous pharmacovigilance reports by quantifying risks in large and diverse patient populations.

Why clinical-trial data are not enough

Before authorisation, a medicine is usually studied in a limited and selected population for a limited period. After launch, evidence accumulates in older adults, children, pregnant patients, people with comorbidities, polypharmacy and long-term exposure. Rare and delayed risks may only become apparent under real-world conditions.

Main real-world data sources

• electronic health records and insurance claims;
• disease, product and pregnancy registries;
• prescribing, dispensing and hospital data;
• post-authorisation non-interventional studies;
• individual case safety reports and pharmacovigilance databases;
• patient-generated and digital data with appropriate quality controls.

Common study designs

• Cohort studies compare outcome rates in exposed and comparator groups.
• Case-control studies compare previous exposure among patients with and without an outcome.
• Self-controlled designs compare risk and control periods within the same person.
• Drug-utilisation studies assess prescribing, dose, adherence and potentially inappropriate use.

ICH M14 and real-world evidence

The ICH M14 guideline reached Step 4 in 2025. It provides harmonised principles for planning non-interventional studies using real-world data for post-marketing safety assessment. Key elements include a prespecified question, fit-for-use data, a transparent protocol, control of confounding and bias, traceable analyses and reproducible results.

Study-quality checklist

1. Define the research question, population, exposure, comparator and outcome.
2. Conduct a feasibility assessment and confirm that data are fit for the intended purpose.
3. Finalise the protocol and statistical analysis plan before outcome analysis.
4. Define and validate algorithms for exposure, outcomes and covariates.
5. Address confounding by indication, selection, missing data and misclassification.
6. Document data provenance, transformations, quality controls and sensitivity analyses.
7. Interpret associations in light of limitations: statistical association does not automatically establish causality.

Role in pharmacovigilance

Pharmacoepidemiology can confirm and quantify signals, identify risk factors, describe medicine use, evaluate risk-minimisation effectiveness and support benefit–risk decisions. Study results should connect with the RMP, PSUR/PBRER and signal-management process.

Official sources

• ICH M14: use of real-world data for safety assessment of medicines
• EMA: Real-world evidence
• EMA: Good Pharmacovigilance Practices
• WHO: Pharmacovigilance

How PharmExpert can help

PharmExpert supports post-authorisation study protocols, real-world data feasibility assessments, analysis plans and integration of evidence into pharmacovigilance and risk-management systems.

This article is for general information. Each study must comply with applicable regulatory, ethical and legal requirements.